Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide Abstract #1795

Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.
Aim(s): To characterize the PK profile and to assess the efficacy, safety and tolerability of oct sc depot vs long-acting oct.
Materials and methods: Adult pts with functioning NETs or acromegaly treated for ≥2 months with long-acting oct (10/20/30mg every four weeks [q4w]) received the last dose of long-acting oct in period 0 (P0) and were randomized 28 days later to receive oct sc depot 10mg every two weeks (q2w) or 20mg q4w for 3 months (period 1 [P1]).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Marianne Pavel

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result